How Covered Entities and Pharma Companies Can Better Collaborate on Drug Discount Programs
Three things drug manufacturers and CEs can do to build trust and enable effective collaboration
The Senate Attacks on Pharma Put the Industry in Jeopardy and Consumers at Risk
Singling out an industry segment won’t solve the underlying problem of healthcare costs.
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
presented by
Unlocking Transparency in PBM Pricing
Dan Reedy, senior director of pricing and underwriting for Abarca, spoke recently with MedCity News about what payers should consider as they explore new models and press for greater transparency.
Don’t Let Inflation Bloat Your Drug Spending
Smart but easy tech upgrades can boost margins.
MedCity News Launches Debunked, A Show Where We Slaughter Myths, Bad Practices and Sacred Cows in Healthcare
MedCity News is launching a new ongoing show called Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare. In this show, co-hosts Arundhati Parmar and Samir Batra will discuss healthcare news and call out things that seem utterly insane to us. The goal is to inspire change in the healthcare industry.
Pharma Just Increased the Price of Hundreds of Drugs. PBMs are Minimizing the Impact for Health Plans, Employers and Patients
While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Healthcare Docket: Will Florida’s Plan to Import Drugs From Canada Open the Floodgates?
No matter the outcome, it’s certain that the cost of drugs will not be an issue easily resolved anytime soon even though several other states also have laws allowing for drug imports.
Walgreens to Pay Humana $360M to Settle Claims It Overcharged for Drugs
Walgreens has agreed to pay Humana $360 million to settle a drug pricing dispute that has spanned nearly five years. The payout is roughly half of what Walgreens was originally ordered to pay when the issue was first resolved last year.
What Was the Most-Repeated Word in CVS Health CEO’s JPM Presentation?
The word has gained greater urgency in recent years as the consumer trend in healthcare has forced payers, providers and all other kinds of healthcare stakeholders to swear by it.
Rising Cost of New Medications, Will the People Who Need Them Most be able to Afford them?
Healthcare has traditionally been built around the convenience of the provider and not the patient. Worse, it tends to treat all patients the same regardless of the condition they are trying to manage. If we want to improve medication compliance, we have to make access, support, and most importantly financial assistance a priority.
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
PBMs Are in Regulators’ Crosshairs But Are Regulators Missing the Point?
Proposals targeting misaligned financial incentives, price transparency, and pharmacy access are important and necessary reforms. But the consequences of failing to address pharmacy benefit managers’ use of market power to block competition and extract monopoly profits from payers and consumers will not be limited to drug costs – it will change all of healthcare for generations.
The Inflation Reduction Act’s Impact on Drug Development for Rare Diseases
Despite these wins for many patients, the new law is already impacting the discovery and development of new drugs for people living with orphan diseases. Not only are drugs that could treat more than one disease being disincentivized, small molecule medicines, which play an important role in treating neurological disorders, cancers, and other diseases, may also be disadvantaged by the law.
Here’s Why Many Americans Are Unable to Afford Their Drugs
Pharmaceutical manufacturers say high U.S. prices support research and development and point out that Americans tend to get new treatments first. But recent research has shown that the price of a drug is related neither to the amount of research and development required to bring it to market nor its therapeutic value.
Lawsuits Against Medicare Drug Negotiations Are Mounting, But They Probably Won’t Be Able to Stop The Plan
Lawsuits filed in opposition to the White House's drug pricing negotiation program are beginning to mount, but legal experts agree that the plaintiffs’ arguments probably won’t hold up during a court battle. However, these lawsuits still could delay when the government's ability to negotiate price goes into effect.
Why One Healthcare Lawyer Thinks Merck’s Drug Pricing Lawsuit Defense ‘Makes No Sense’
Merck recently became the first drugmaker to sue the federal government over its Medicare drug price negotiation program. The company's lawsuit argues that the program violates the Constitution’s First and Fifth Amendments, but healthcare law expert Robin Feldman said the defense doesn't have any legs.